DDInter1351 DDInter1376
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zileuton
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Osilodrostat may lead to a major life threatening interaction when taken with Tizanidine
Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib